Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.

Vink FJ, Meijer CJLM, Clifford GM, Poljak M, Oštrbenk A, Petry KU, Rothe B, Bonde J, Pedersen H, de Sanjosé S, Torres M, Del Pino M, Quint WGV, Cuschieri K, Alcañiz Boada E, van Trommel NE, Lissenberg-Witte BI, Floore AN, Hesselink AT, Steenbergen RDM, Bleeker MCG, Heideman DAM.

Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614. [Epub ahead of print]

PMID:
31390052
2.

A Prospective Cohort Study of Human Papillomavirus-Driven Oropharyngeal Cancers: Implications for Prognosis and Immunisation.

Wakeham K, Pan J, Pollock KG, Millan D, Bell S, McLellan D, McPhaden A, Conway DI, Graham SV, Kavanagh K, Cuschieri K.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):e132-e142. doi: 10.1016/j.clon.2019.05.010. Epub 2019 Jun 25.

PMID:
31248692
3.

Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies.

Xu L, Benoy I, Cuschieri K, Poljak M, Bonde J, Arbyn M.

Expert Rev Mol Diagn. 2019 Jun;19(6):543-551. doi: 10.1080/14737159.2019.1613890. Epub 2019 May 8.

PMID:
31035813
4.

HPV infection and pre-term birth: a data-linkage study using Scottish Health Data.

Aldhous MC, Bhatia R, Pollock R, Vragkos D, Cuschieri K, Cubie HA, Norman JE, Stock SJ.

Wellcome Open Res. 2019 Mar 8;4:48. doi: 10.12688/wellcomeopenres.15140.1. eCollection 2019.

5.

Factors That Influence Confirmation of Neisseria gonorrhoeae Positivity by Molecular Methods.

Cuschieri K, Shepherd J, Graham C, Guerendiain D, Templeton KE.

J Clin Microbiol. 2019 May 24;57(6). pii: e02068-18. doi: 10.1128/JCM.02068-18. Print 2019 Jun.

PMID:
30944196
6.

Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M.

BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161.

7.

Human Papillomavirus Research: Where Should We Place Our Bets?

Cuschieri K, Lorincz AT, Nedjai B.

Acta Cytol. 2019;63(2):85-96. doi: 10.1159/000493800. Epub 2019 Mar 28. Review.

8.

Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study.

Floore A, Hesselink A, Oštrbenk A, Alcaniz E, Rothe B, Pedersen H, Torres Hortal M, Doorn S, Quint W, Petry KU, Poljak M, Cuschieri K, Bonde J, de Sanjosé S, Bleeker M, Heideman D.

J Clin Lab Anal. 2019 May;33(4):e22854. doi: 10.1002/jcla.22854. Epub 2019 Feb 13.

PMID:
30758084
9.

Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing.

Cuschieri K, Schuurman R, Coughlan S.

Cytopathology. 2019 May;30(3):273-280. doi: 10.1111/cyt.12679. Epub 2019 Feb 18. Review.

PMID:
30657615
10.

The potential of biobanked liquid based cytology samples for cervical cancer screening using Raman spectroscopy.

Traynor D, Duraipandian S, Bhatia R, Cuschieri K, Martin CM, O'Leary JJ, Lyng FM.

J Biophotonics. 2019 Jul;12(7):e201800377. doi: 10.1002/jbio.201800377. Epub 2019 Mar 25.

PMID:
30653819
11.

Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.

Pan J, Kavanagh K, Cuschieri K, Pollock KG, Gilbert DC, Millan D, Bell S, Graham SV, Williams ARW, Cruickshank ME, Palmer T, Wakeham K.

Int J Cancer. 2019 Jul 15;145(2):427-434. doi: 10.1002/ijc.32126. Epub 2019 Mar 4.

PMID:
30650180
12.

Baseline HPV prevalence in rectal swabs from men attending a sexual health clinic in Scotland: assessing the potential impact of a selective HPV vaccination programme for men who have sex with men.

Cameron RL, Cuschieri K, Pollock KGJ.

Sex Transm Infect. 2019 Jan 13. pii: sextrans-2018-053668. doi: 10.1136/sextrans-2018-053668. [Epub ahead of print]

PMID:
30636708
13.

Development of an in-house ELISA to detect anti-HPV16-L1 antibodies in serum and dried blood spots.

Bhatia R, Stewart J, Moncur S, Cubie H, Kavanagh K, Pollock KGJ, Busby-Earle C, Williams ARW, Howie S, Cuschieri K.

J Virol Methods. 2019 Feb;264:55-60. doi: 10.1016/j.jviromet.2018.10.007. Epub 2018 Oct 22.

PMID:
30352214
14.

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.

Bonde J, Ejegod DM, Cuschieri K, Dillner J, Heideman DAM, Quint W, Pavon Ribas MA, Padalko E, Christiansen IK, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:64-71. doi: 10.1016/j.jcv.2018.09.012. Epub 2018 Sep 17.

15.

Validation of EUROArray HPV test using the VALGENT framework.

Viti J, Poljak M, Oštrbenk A, Bhatia R, Alcañiz Boada E, Cornall AM, Cuschieri K, Garland S, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:38-42. doi: 10.1016/j.jcv.2018.09.005. Epub 2018 Sep 10.

PMID:
30223253
16.

Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples.

Stevenson A, Kavanagh K, Pan J, Stevenson L, Griffin H, Doorbar J, Scott E, Deeny M, Cuschieri K, Graham SV.

J Clin Virol. 2018 Nov;108:19-25. doi: 10.1016/j.jcv.2018.08.011. Epub 2018 Aug 31.

17.

VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.

Arbyn M, Peeters E, Benoy I, Vanden Broeck D, Bogers J, De Sutter P, Donders G, Tjalma W, Weyers S, Cuschieri K, Poljak M, Bonde J, Cocuzza C, Zhao FH, Van Keer S, Vorsters A.

J Clin Virol. 2018 Oct;107:52-56. doi: 10.1016/j.jcv.2018.08.006. Epub 2018 Aug 22.

PMID:
30195193
18.

Squamous cell carcinoma in the anophthalmic socket: a series of four cases with HPV-16 profiling.

McGrath LA, Salvi SM, Sandramouli S, Bhatt R, Cuschieri K, Mudhar HS.

Br J Ophthalmol. 2018 Jun 28. pii: bjophthalmol-2018-311916. doi: 10.1136/bjophthalmol-2018-311916. [Epub ahead of print]

PMID:
29954784
19.

Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions.

Bhatia R, Kavanagh K, Stewart J, Moncur S, Serrano I, Cong D, Cubie HA, Haas JG, Busby-Earle C, Williams ARW, Howie SEM, Cuschieri K.

Oncotarget. 2018 Apr 6;9(26):18548-18558. doi: 10.18632/oncotarget.24946. eCollection 2018 Apr 6.

20.

Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Aug 15;143(4):735-745. doi: 10.1002/ijc.31261. Epub 2018 Feb 8. Review.

21.

Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.

Bhatia R, Serrano I, Wennington H, Graham C, Cubie H, Boland E, Fu G, Cuschieri K.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01687-17. doi: 10.1128/JCM.01687-17. Print 2018 Mar.

22.

RNA-Seq Analysis of Differentiated Keratinocytes Reveals a Massive Response to Late Events during Human Papillomavirus 16 Infection, Including Loss of Epithelial Barrier Function.

Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, Pollock C, Bhatia R, Cuschieri K, Herzyk P, Gatherer D, Graham SV.

J Virol. 2017 Nov 30;91(24). pii: e01001-17. doi: 10.1128/JVI.01001-17. Print 2017 Dec 15.

23.

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.

Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, Robertson C.

Lancet Infect Dis. 2017 Dec;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1. Epub 2017 Sep 28.

PMID:
28965955
24.

Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.

Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, Patterson L, Govan L, Black J, Palmer T, Arbyn M.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1629-1635. doi: 10.1158/1055-9965.EPI-17-0534. Epub 2017 Sep 8.

25.

The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.

Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG.

J Epidemiol Community Health. 2017 Oct;71(10):954-960. doi: 10.1136/jech-2017-209113. Epub 2017 Jul 29.

26.

The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.

Munro A, Gillespie C, Cotton S, Busby-Earle C, Kavanagh K, Cuschieri K, Cubie H, Robertson C, Smart L, Pollock K, Moore C, Palmer T, Cruickshank ME.

BJOG. 2017 Aug;124(9):1394-1401. doi: 10.1111/1471-0528.14563. Epub 2017 Mar 9.

27.

Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.

Cruickshank ME, Pan J, Cotton SC, Kavanagh K, Robertson C, Cuschieri K, Cubie H, Palmer T, Pollock KG.

BJOG. 2017 Aug;124(9):1386-1393. doi: 10.1111/1471-0528.14562. Epub 2017 Mar 9.

28.

HPV status and favourable outcome in vulvar squamous cancer.

Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, Burton K, Reed NS, Graham SV.

Int J Cancer. 2017 Mar 1;140(5):1134-1146. doi: 10.1002/ijc.30523.

29.

Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings.

Conway DI, Robertson C, Gray H, Young L, McDaid LM, Winter AJ, Campbell C, Pan J, Kavanagh K, Kean S, Bhatia R, Cubie H, Clarkson JE, Bagg J, Pollock KG, Cuschieri K.

PLoS One. 2016 Nov 18;11(11):e0165847. doi: 10.1371/journal.pone.0165847. eCollection 2016.

30.

HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology.

Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, Rapozo D, Long A, Cubie H, Junor E, Monaghan H, Harrington KJ, Nutting CM, Schick U, Lau AS, Upile N, Sheard J, Brougham K, West CM, Oguejiofor K, Thomas S, Ness AR, Pring M, Thomas GJ, King EV, McCance DJ, James JA, Moran M, Sloan P, Shaw RJ, Evans M, Jones TM.

Cancer Res. 2016 Nov 15;76(22):6598-6606. doi: 10.1158/0008-5472.CAN-16-0633. Epub 2016 Aug 28.

31.

Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma.

Pattle SB, Utjesanovic N, Togo A, Wells L, Conn B, Monaghan H, Junor E, Johannessen I, Cuschieri K, Talbot S.

Genes Chromosomes Cancer. 2017 Mar;56(3):185-198. doi: 10.1002/gcc.22425. Epub 2016 Nov 21.

32.

Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M.

J Clin Microbiol. 2016 Sep;54(9):2337-42. doi: 10.1128/JCM.00897-16. Epub 2016 Jul 6.

33.

Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.

Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N.

Br J Cancer. 2016 Jul 12;115(2):212-22. doi: 10.1038/bjc.2016.199. Epub 2016 Jun 28.

34.

Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MNC, van Doorn LJ, Snijders PJF, Meijer CJLM, Quint WGV, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.

35.

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.

Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M.

J Clin Virol. 2016 Aug;81:6-11. doi: 10.1016/j.jcv.2016.05.004. Epub 2016 May 19.

PMID:
27262102
36.

Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.

Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG.

Br J Cancer. 2016 May 24;114(11):1261-4. doi: 10.1038/bjc.2016.97. Epub 2016 Apr 26.

37.

Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, Arbyn M.

BMJ Open. 2016 Apr 25;6(4):e010660. doi: 10.1136/bmjopen-2015-010660.

38.

Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.

Moore C, Duvall E, Braby E, Reid G, Docherty E, Grieve L, Cubie H, Graham C, Cuschieri K.

J Clin Virol. 2016 Jun;79:32-35. doi: 10.1016/j.jcv.2016.03.020. Epub 2016 Mar 22.

PMID:
27060653
39.

HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Cotton S, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):582-9. doi: 10.1038/bjc.2015.474. Epub 2016 Feb 4.

40.

Formalin fixed paraffin embedded (FFPE) material is amenable to HPV detection by the Xpert(®) HPV assay.

Guerendiain D, Moore C, Wells L, Conn B, Cuschieri K.

J Clin Virol. 2016 Apr;77:55-9. doi: 10.1016/j.jcv.2016.02.007. Epub 2016 Feb 11. Erratum in: J Clin Virol. 2016 Apr;77:116.

PMID:
26896874
41.

Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women.

Leonard SM, Pereira M, Roberts S, Cuschieri K, Nuovo G, Athavale R, Young L, Ganesan R, Woodman CB.

Sci Rep. 2016 Feb 15;6:20847. doi: 10.1038/srep20847.

42.

Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.

Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, Pan J, Pollock KG, Palmer TJ, Cuschieri K.

Int J Cancer. 2016 Jun 15;138(12):2922-31. doi: 10.1002/ijc.30030. Epub 2016 Feb 26.

43.

HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):576-81. doi: 10.1038/bjc.2015.473. Epub 2016 Jan 22.

44.

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.

Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KG.

Emerg Infect Dis. 2016 Jan;22(1):56-64. doi: 10.3201/eid2201.150736.

45.

HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.

Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E.

J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28. doi: 10.1016/j.jcv.2015.10.025. Epub 2015 Nov 10. Review.

PMID:
26669512
46.

HPV testing in the context of post-treatment follow up (test of cure).

Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S56-S61. doi: 10.1016/j.jcv.2015.10.008. Epub 2015 Oct 22. Review.

PMID:
26525202
47.

VALGENT: A protocol for clinical validation of human papillomavirus assays.

Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W.

J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21. doi: 10.1016/j.jcv.2015.09.014. Epub 2015 Oct 8. Review.

PMID:
26522865
48.

The role of infection in miscarriage.

Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW.

Hum Reprod Update. 2016 Jan-Feb;22(1):116-33. doi: 10.1093/humupd/dmv041. Epub 2015 Sep 19. Review.

49.

Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M.

J Clin Microbiol. 2015 Oct;53(10):3272-9. doi: 10.1128/JCM.01366-15. Epub 2015 Aug 5.

50.

Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine.

Hanley SJ, Pollock KG, Cuschieri K.

Intern Med. 2015;54(15):1953. doi: 10.2169/internalmedicine.54.4479. Epub 2015 Aug 1. No abstract available.

Supplemental Content

Loading ...
Support Center